7 completed, 1 recruiting. 4 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow Lenalidomide (Revlimid®): new trials by email Literature Review of Lenalidomide (Revlimid®) trials Research Report on Lenalidomide (Revlimid®)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex) - Multiple Myeloma, Newly Diagnosed | Phase 3 | Recruiting | Intergroupe Francophone du Myelome | 824 | 2025-07-09 | 2026-09-30 |
| Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old bortezomib (Velcade ®), lenalidomide (Revlimid®), busulfan (Busilvex ®) - Multiple Myeloma | Phase 3 | Completed | PETHEMA Foundation | 460 | 2013-09-01 | 2017-09-27 |
| Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years Lenalidomide, Bortezomib - Myeloma | Phase 3 | Completed | University Hospital, Toulouse | 700 | 2010-10-01 | 2026-04-06 |
| Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Ezatiostat Hydrochloride, Lenalidomide (Revlimid®) - Myelodysplastic Syndrome | Phase 1 | Completed | Telik | 19 | 2009-11-01 | 2013-06-06 |
| Frontline Therapy in de Novo Multiple Myeloma Patients Under 65 Lenalidomide, Bortezomib - Multiple Myeloma | Phase 2 | Completed | University Hospital, Toulouse | 31 | 2009-08-01 | 2017-05-12 |
| Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) Idarubicin, Cytarabine, Lenalidomide (Revlimid®) - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 51 | 2009-06-25 | 2020-12-22 |
| Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma lenalidomide (Revlimid®), Cyclophosphamide, Prednisone - Multiple Myeloma | Phase 2 | Completed | Attaya Suvannasankha | 70 | 2007-10-01 | 2016-06-21 |
| Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma Lenalidomide (Revlimid®) - Hodgkin Disease | Phase 2 | Completed | University Health Network, Toronto | 30 | 2006-12-01 | 2020-09-18 |
Multiple Myeloma (4) · Myelodysplastic Syndromes (2) · Disease Progression (1) · Hodgkin Disease (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Neoplasms, Plasma Cell (1)
University Hospital, Toulouse (2) · Attaya Suvannasankha (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Intergroupe Francophone du Myelome (1) · PETHEMA Foundation (1) · Telik (1) · University Health Network, Toronto (1)
France (3) · United States (3) · Belgium (1) · Spain (1)
Attaya Suvannasankha, M.D. (1) · Gail Brown, M.D. (1) · Jeffrey Lancet, M.D. (1) · John Kuruvilla (1)
PMID 38023148, PMID 22546242, PMID 23194056, PMID 25024076, PMID 28379796, PMID 31484647, PMID 32090636, PMID 32687451, PMID 32693406, PMID 34587246, PMID 34643690, PMID 35157768, PMID 36828828, PMID 37646661, PMID 38031761, PMID 38048552, PMID 39293025, PMID 40499010
2009 (1)